- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03452475
Comparison of Arterolane-piperaquine Versus Arterolane-piperaquine+Mefloquine Versus Artemether-lumefantrine in Kenyan Children (TACTKenya)
An Open-label Randomised Trial to Assess the Therapeutic Efficacy and Tolerability of Arterolane-piperaquine Plus Single Low Dose Primaquine Versus Arterolane-piperaquine Plus Mefloquine and Single Low Dose Primaquine Versus Artemether-lumefantrine Plus Single Low Dose Primaquine in the Treatment of Uncomplicated Falciparum Malaria in Children in Kenya
This open-label randomised controlled clinical trial will compare the safety, tolerability, therapeutic efficacy and pharmacokinetics and pharmacodynamics of arterolane-piperaquine, arterolane-piperaquine plus mefloquine versus artemether-lumefantrine.in children with uncomplicated falciparum malaria in Kilifi, Kenya. This study will also provide an up to date insight on the current presence of antimalarial resistance in this site.
In addition, all children will be treated with a single low dose of primaquine, dosing is age based.
The investigators will recruit 219 patients aged 2 years to 12 years with acute uncomplicated falciparum malaria in Kilifi County Hospital.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Kilifi, Kenya, P.O Box P.O. Box 9
- Kilifi County Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or female aged 2 years to <13-year-old
Uncomplicated falciparum malaria as defined as:
- Positive blood smear with asexual forms of P. falciparum (may be mixed with non-falciparum species)
- Parasitaemia between 5,000-250,000 parasites/µL
- Fever defined as tympanic temperature >37.5°C or history of fever within last 48 hours
- Ability to take oral medication
- Willingness and ability to comply with study protocol for study duration
- Written informed consent given to participate in the trial
Exclusion Criteria:
- Signs of severe/complicated malaria*
- Any clinical reason suggesting that the child's treatment should be given immediately and not delayed during the transfer to Kilifi County Hospital in the opinion of the treating physician.
- Acute illness other than malaria requiring urgent systemic treatment as assessed by the treating physician
- Previous splenectomy
- Treatment with artemisinin or ACT within the previous 7 days
- Treatment with mefloquine in the 2 months prior to presentation
- Known hypersensitivity or contraindication to arterolane-piperaquine, DHA-piperaquine, artemisinin, mefloquine (epilepsy, major psychiatric illness) or primaquine
- QTc interval >450 milliseconds at point of presentation
- Known personal or family history of cardiac conduction problems
- Participation within another clinical trial in the previous 3 months
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Arterolane-piperaquine
Arterolane-piperaquine for 3 days
|
Arterolane maleate-piperaquine phosphate tablets (37.5 mg/187.5 mg)
|
Active Comparator: Arterolane-piperaquine+mefloquine
Arterolane-piperaquine + mefloquine for 3 days
|
Arterolane maleate-piperaquine phosphate tablets (37.5 mg/187.5 mg) Mefloquine tablets (250 mg)
|
Active Comparator: Artemether-lumefantrine
Artemether-lumefantrine for 3 days
|
Artemether-lumefantrine tablets (20 mg/120 mg)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
42-day PCR corrected adequate clinical and parasitological response (ACPR) by day 42 by study arm
Time Frame: 42 days
|
42 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Parasite clearance half-life
Time Frame: 42 days
|
Parasite clearance half-life is assessed by entering the parasite counts (assessed by microscopy) in the WWARN PCE calculator
|
42 days
|
Parasite reduction rates
Time Frame: 24 and 48 hours
|
Parasite reduction rates and ratios at 24 and 48 hours assessed by microscopy
|
24 and 48 hours
|
Parasite count to fall 50%
Time Frame: 42 days
|
Time for parasite count to fall 50% of initial parasite density
|
42 days
|
Parasite count to fall 90%
Time Frame: 42 days
|
Time for parasite count to fall 90% of initial parasite density
|
42 days
|
Fever clearance time
Time Frame: 42 days
|
The time taken for the tympanic temperature to fall below 37.5˚C and remain there for at least 24 hours
|
42 days
|
Incidence of clinical adverse events and serious adverse events
Time Frame: 42 days
|
42 days
|
|
Incidence of adverse events concerning markers of hepatic or renal toxicity
Time Frame: 42 days
|
Total bilirubin, Alanine transaminase, Aspartate transaminase, Alkaline phosphatase and creatinine will be measured
|
42 days
|
Incidence of prolongation of the corrected QT interval
Time Frame: 42 days
|
Incidence of the prolongation of the corrected QT interval above 500 ms or > 60 ms above baseline values
|
42 days
|
Prolongation of the corrected QT interval
Time Frame: Baseline, hour 4, hour 24, hour 28, hour 48 and hour 52
|
Prolongation of the corrected QT interval compared at hour 4, hour 24, hour 28, hour 48 and hour 52 compared to baseline
|
Baseline, hour 4, hour 24, hour 28, hour 48 and hour 52
|
Change in haematocrit
Time Frame: Baseline, hour 24, hour 48, hour 72, day 7, day 14, day 21, day 28, day 35 and day 42
|
Change in haematocrit at hour 24, hour 48, hour 72, day 7, day 14, day 21, day 28, day 35 and day 42 according to geographical location and study arm, stratified for G6PD status
|
Baseline, hour 24, hour 48, hour 72, day 7, day 14, day 21, day 28, day 35 and day 42
|
Proportion of patients that reports completing a full course of observed TACT or ACT
Time Frame: 42 days
|
Proportion of patients that reports completing a full course of observed TACT or ACT without withdrawal of consent or exclusion from study because of drug related serious adverse event
|
42 days
|
Prevalence of Kelch13 mutations of known significance
Time Frame: Baseline
|
Prevalence of Kelch13 mutations of known significance
|
Baseline
|
Prevalence/incidence of other genetic markers of antimalarial drug resistance such as multidrug resistance gene 1 copy number and multidrug resistance gene 1 mutations
Time Frame: Baseline
|
Prevalence/incidence of other genetic markers of antimalarial drug resistance such as multidrug resistance gene 1 copy number and multidrug resistance gene 1 mutations
|
Baseline
|
Genome wide association with in vivo/in vitro sensitivity parasite phenotype
Time Frame: Baseline
|
Genome wide association with in vivo/in vitro sensitivity parasite phenotype
|
Baseline
|
A comparison of transcriptomic patterns between sensitive and resistant parasites
Time Frame: Baseline and 6 hours
|
Transcriptomic patterns measure at baseline and at specified time points after the start of treatment comparing sensitive and resistant parasites
|
Baseline and 6 hours
|
Proportion of patients with gametocytaemia before, during and after treatment
Time Frame: 42 days
|
Proportion of patients with gametocytaemia before, during and after treatment
|
42 days
|
Levels of RNA transcription coding for male or female gametocytes
Time Frame: Baseline
|
Levels of RNA transcription coding for male or female gametocytes at admission
|
Baseline
|
In vitro sensitivity of P. falciparum to artemisinins and partner drugs
Time Frame: Baseline and day recurrent infection
|
Baseline and day recurrent infection
|
|
Pharmacokinetic profiles and interactions (Cmax) of arterolane and partner drugs
Time Frame: 42 days
|
Pharmacokinetic profiles and interactions (Cmax) of arterolane and partner drugs
|
42 days
|
Day 7 drug levels of partner drugs in association with treatment efficacy and treatment arm
Time Frame: 7 days
|
Day 7 drug levels of partner drugs in association with treatment efficacy and treatment arm
|
7 days
|
Data on recent travel and current location of living
Time Frame: Baseline
|
Baseline
|
Collaborators and Investigators
Sponsor
Collaborators
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- MAL17009
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Plasmodium Falciparum
-
SanofiMedicines for Malaria VentureCompletedPlasmodium Falciparum InfectionBenin, Burkina Faso, Gabon, Kenya, Uganda
-
SanofiMedicines for Malaria VentureTerminatedPlasmodium Falciparum InfectionBenin, Burkina Faso, Gabon, Kenya, Mozambique, Uganda, Vietnam
-
Syamsudin Abdillah,Ph.D, Pharm DApt. Dian Yudianto; Dr. dr Erni J. Nelwan, Sp.PD, Ph.D; Apt.Hesty Utami Ramadaniati...CompletedUncomplicated Plasmodium FalciparumIndonesia
-
Novartis PharmaceuticalsRecruitingUncomplicated Plasmodium Falciparum MalariaCôte D'Ivoire, Kenya, Ghana, Uganda
-
Medicines for Malaria VentureCompletedUncomplicated Plasmodium Falciparum MalariaUganda, Benin, Burkina Faso, Congo, The Democratic Republic of the, Gabon, Mozambique, Vietnam
-
Karolinska University HospitalMuhimbili University of Health and Allied SciencesCompletedUncomplicated Plasmodium Falciparum MalariaTanzania
-
University of OxfordEuropean CommissionCompletedMalaria | Plasmodium FalciparumUnited Kingdom
-
University of OxfordRecruitingMalaria | Plasmodium FalciparumUnited Kingdom
-
University of OxfordEuropean and Developing Countries Clinical Trials Partnership (EDCTP); Medical...RecruitingMalaria, Plasmodium FalciparumGambia
-
PfizerCompletedPLASMODIUM FALCIPARUM MALARIAIndia
Clinical Trials on Arterolane-piperaquine
-
University of OxfordMahidol Oxford Tropical Medicine Research Unit; Department of Medical Research...WithdrawnUncomplicated Falciparum Malaria | Artemisinin-resistant
-
Medicines for Malaria VentureCompletedUncomplicated Plasmodium Falciparum MalariaUganda, Benin, Burkina Faso, Congo, The Democratic Republic of the, Gabon, Mozambique, Vietnam
-
Medicines for Malaria VentureCompleted
-
Novartis PharmaceuticalsMedicine for Malaria VentureTerminatedPlasmodium Falciparum MalariaAustralia
-
University of OxfordMahidol Oxford Tropical Medicine Research UnitCompleted
-
Richard MwaisweloNational Institute for Medical Research, Tanzania; Muhimbili University of... and other collaboratorsCompletedMalaria | Chemoprophylaxis | Underfive ChildrenTanzania
-
Menzies School of Health ResearchWorld Health Organization; Eijkman Institute for Molecular BiologyCompletedPlasmodium Falciparum Infection | Plasmodium Vivax InfectionIndonesia
-
London School of Hygiene and Tropical MedicineMedical Research Council Unit, The GambiaTerminated
-
University of California, San FranciscoMahidol University; Holley-Cotec Pharmaceuticals Co., LTD.Completed
-
National Institute for Medical Research, TanzaniaNational Malaria Control Program, TanzaniaActive, not recruiting